| A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (NCT02014480) | GlaxoSmithKline | 2013-02-01 |
| Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults (NCT01738477) | GlaxoSmithKline | 2013-01-31 |
| The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD (NCT01777334) | GlaxoSmithKline | 2013-01-23 |
| A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors (NCT01738451) | GlaxoSmithKline | 2013-01-22 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2256294 in Healthy Volunteers, and Single and Repeat Doses of GSK2256294 in Adult Male Moderately Obese Smokers (NCT01762774) | GlaxoSmithKline | 2013-01-16 |
| A Study in Healthy Volunteers to Evaluate the Application of Stable Isotope Approach to Reduce Number of Subjects Needed for PK Studies (NCT01793870) | GlaxoSmithKline | 2013-01-15 |
| Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults (NCT01755689) | GlaxoSmithKline | 2013-01-11 |
| Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age (NCT01767376) | GlaxoSmithKline | 2013-01-10 |
| A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin (NCT01756495) | GlaxoSmithKline | 2013-01-10 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of the Dry Powder Formulation of GSK2269557 in Healthy Subjects (NCT01762878) | GlaxoSmithKline | 2013-01-09 |
| GSK239512 DDI Study (NCT01802931) | GlaxoSmithKline | 2013-01-07 |
| Study to Assess the Burden of Mild Outcomes (Physician Office Visits) Due to Influenza in the United States (NCT02019732) | GlaxoSmithKline | 2013-01-01 |
| Panadol Osteo Pharmaceuticals Benefit Scheme (PBS) Claims Cohort Study (NCT02262702) | GlaxoSmithKline | 2013-01-01 |
| Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks. (NCT01772147) | GlaxoSmithKline | 2013-01-01 |
| Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks (NCT01772134) | GlaxoSmithKline | 2013-01-01 |
| Neisseria Meningitidis Burden of Disease Study (NCT01730391) | GlaxoSmithKline | 2013-01-01 |
| Exploratory Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity (NCT01831817) | GlaxoSmithKline | 2013-01-01 |
| Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis (NCT01753076) | GlaxoSmithKline | 2012-12-20 |
| Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures (NCT01721317) | GlaxoSmithKline | 2012-12-19 |
| To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers (NCT01751074) | GlaxoSmithKline | 2012-12-17 |
| A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects (NCT01691547) | GlaxoSmithKline | 2012-12-17 |
| To Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Social Drinkers (NCT01738867) | GlaxoSmithKline | 2012-12-12 |
| Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers (NCT01577732) | GlaxoSmithKline | 2012-12-08 |
| Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old (NCT01730378) | GlaxoSmithKline | 2012-12-05 |
| Relovair PD PK in Chinese Healthy Subjects (NCT01711463) | GlaxoSmithKline | 2012-12-05 |
| Assessment of Fluticasone Propionate on Ocular Allergy Symptoms (NCT01817790) | GlaxoSmithKline | 2012-12-01 |
| A Study to Estimate the Occurrence of Rotavirus Gastroenteritis in Children < 5 Years of Age, in Bulgaria and Latvia (NCT01733849) | GlaxoSmithKline | 2012-12-01 |
| Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH) (NCT01808313) | GlaxoSmithKline | 2012-12-01 |
| Study to Assess the Impact of Vaccination on Hospitalizations and Outpatient Visits Due to Rotavirus Gastroenteritis (NCT01733862) | GlaxoSmithKline | 2012-11-27 |
| Belimumab Assessment of Safety in SLE (NCT01705977) | GlaxoSmithKline | 2012-11-27 |
| Nebulized Fluticasone Propionate VS Oral Prednisone in Chinese Pediatric and Adolescent Subjects With an Acute Exacerbation of Asthma (NCT01687296) | GlaxoSmithKline | 2012-11-12 |
| Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age (NCT01702428) | GlaxoSmithKline | 2012-11-09 |
| To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI) (NCT01725685) | GlaxoSmithKline | 2012-11-08 |
| Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects (NCT01702480) | GlaxoSmithKline | 2012-11-05 |
| Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret) (NCT01802892) | GlaxoSmithKline | 2012-11-02 |
| Sero-prevalence of Anti-pertussis Antibodies and Disease Awareness Among Spanish Healthcare Professionals (NCT01706224) | GlaxoSmithKline | 2012-11-01 |
| RELOVAIR® Lung Deflation Study (NCT01691885) | GlaxoSmithKline | 2012-11-01 |
| An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma (NCT01706198) | GlaxoSmithKline | 2012-11-01 |
| Study to Identify and Characterize Bacteria Causing Acute Otitis Media in Young Children in Turkey (NCT01031329) | GlaxoSmithKline | 2012-11-01 |
| WEUSKOP5723: Prostate Cancer Study (NCT01767363) | GlaxoSmithKline | 2012-11-01 |
| ALTARGO(Retapamulin) PMS(Post-marketing Surveillance) (NCT01445600) | GlaxoSmithKline | 2012-11-01 |
| Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of Age (NCT01711736) | GlaxoSmithKline | 2012-11-01 |
| Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UK (NCT01905462) | GlaxoSmithKline | 2012-11-01 |
| A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment (NCT01711723) | GlaxoSmithKline | 2012-10-29 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers (NCT01702467) | GlaxoSmithKline | 2012-10-19 |
| This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult Subjects (NCT01706315) | GlaxoSmithKline | 2012-10-17 |
| A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (NCT01706328) | GlaxoSmithKline | 2012-10-15 |
| Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old (NCT01627561) | GlaxoSmithKline | 2012-10-15 |
| Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects (NCT01691872) | GlaxoSmithKline | 2012-10-10 |
| Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life (NCT01681992) | GlaxoSmithKline | 2012-10-10 |
| Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma (NCT01691521) | GlaxoSmithKline | 2012-10-08 |
| Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age. (NCT01682876) | GlaxoSmithKline | 2012-10-07 |
| Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine When Administered in Children Who Previously Participated in Study 115345 (NCT01702454) | GlaxoSmithKline | 2012-10-06 |
| A Study in Adolescent Females to Explore Cytomegalovirus Infection (NCT01691820) | GlaxoSmithKline | 2012-10-05 |
| This Study Will Investigate the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, With Moxifloxacin as a Positive Control in Healthy Volunteers. (NCT01702376) | GlaxoSmithKline | 2012-10-03 |
| An Efficacy Study of Chlorhexidine Mouthwashes (NCT01751178) | GlaxoSmithKline | 2012-10-01 |
| Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma (NCT01691508) | GlaxoSmithKline | 2012-10-01 |
| ARIXTRA® Adherence in SVT Patients. (NCT01691495) | GlaxoSmithKline | 2012-10-01 |
| Assess the Risk of Solid Organ Transplant Rejection Following Vaccination With Pandemrix™ in UK (NCT01715792) | GlaxoSmithKline | 2012-10-01 |
| Study to Characterize and Identify Bacteria Causing Acute Otitis Media in Young Egyptian Children (NCT01160055) | GlaxoSmithKline | 2012-10-01 |
| Burden of Respiratory Syncytial Virus (RSV) in the United Kingdom From 1995 to 2009 (NCT01706302) | GlaxoSmithKline | 2012-10-01 |
| Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg (NCT01716520) | GlaxoSmithKline | 2012-10-01 |
| MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects (NCT01691859) | GlaxoSmithKline | 2012-09-28 |
| A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma (NCT01343043) | GlaxoSmithKline | 2012-09-27 |
| Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers (NCT01725672) | GlaxoSmithKline | 2012-09-27 |
| Efficacy and Safety Study of Fluticasone Proponate Inhalation Solution in Adult and Adolescent Asthma (NCT01687283) | GlaxoSmithKline | 2012-09-27 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects (NCT01696604) | GlaxoSmithKline | 2012-09-26 |
| An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma. (NCT01686633) | GlaxoSmithKline | 2012-09-20 |
| A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 (NCT01658553) | GlaxoSmithKline | 2012-09-19 |
| Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects (NCT01641042) | GlaxoSmithKline | 2012-09-10 |
| Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy (NCT01649765) | GlaxoSmithKline | 2012-09-07 |
| Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™ (NCT01641133) | GlaxoSmithKline | 2012-09-04 |
| Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS (NCT01668654) | GlaxoSmithKline | 2012-09-04 |
| A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors (NCT01340846) | GlaxoSmithKline | 2012-09-03 |
| Trobalt™ Products Risk Survey (NCT01721213) | GlaxoSmithKline | 2012-09-01 |
| Glucagon-like Peptide (GLP) Utilization and Safety (NCT01767389) | GlaxoSmithKline | 2012-09-01 |
| Nicotine Mouth Film for Craving Relief. (NCT01702532) | GlaxoSmithKline | 2012-09-01 |
| Aura Adolescent PK Study GSK2829332 (NCT01653483) | GlaxoSmithKline | 2012-09-01 |
| The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury (NCT01597635) | GlaxoSmithKline | 2012-09-01 |
| A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers (NCT01678677) | GlaxoSmithKline | 2012-08-31 |
| Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures (NCT01648101) | GlaxoSmithKline | 2012-08-29 |
| Bioequivalence - Duodart Against Avodart & Omnic (NCT01657851) | GlaxoSmithKline | 2012-08-23 |
| Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age (NCT01659086) | GlaxoSmithKline | 2012-08-22 |
| Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342 (NCT01669096) | GlaxoSmithKline | 2012-08-21 |
| Study to Evaluate the Pharmacokinetics, Safety and Tolerability of GSK557296 in Healthy Women Volunteers After Single and Repeat Dosing (NCT01669083) | GlaxoSmithKline | 2012-08-16 |
| A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI) (NCT01669070) | GlaxoSmithKline | 2012-08-15 |
| A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose (NCT01663389) | GlaxoSmithKline | 2012-08-10 |
| Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine (NCT01657526) | GlaxoSmithKline | 2012-08-08 |
| Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Amlodipine and Losartan in Health Volunteers (NCT01648231) | GlaxoSmithKline | 2012-08-06 |
| Study to Analyze the Clinical and Cost Impact of Complete and Incomplete Rotavirus (RV) Vaccination (NCT01682005) | GlaxoSmithKline | 2012-08-01 |
| Long-term Safety Study for GSK573719 in Japanese (NCT01702363) | GlaxoSmithKline | 2012-08-01 |
| Investigate the Efficacy and Safety of GSK1070806 in Obese Subjects With T2DM (NCT01648153) | GlaxoSmithKline | 2012-08-01 |
| Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity (NCT01691560) | GlaxoSmithKline | 2012-08-01 |
| Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects (NCT01657552) | GlaxoSmithKline | 2012-08-01 |
| Dose Ranging of GSK2336805 in Combination Therapy (NCT01648140) | GlaxoSmithKline | 2012-08-01 |
| Lamotrigine Phase III Study in Bipolar I Disorder (NCT01602510) | GlaxoSmithKline | 2012-08-01 |
| BE Study of Metformin GSK 850mg (NCT01710540) | GlaxoSmithKline | 2012-08-01 |
| Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation (NCT01647659) | GlaxoSmithKline | 2012-07-30 |
| Study in Pediatric Subjects With Epilepsy (NCT01494584) | GlaxoSmithKline | 2012-07-25 |
| Phase I Study of GW856553 (Losmapimod) (NCT01648192) | GlaxoSmithKline | 2012-07-24 |